Hematologic response in patients with confirmed diagnosis of accelerated phase
| Hematologic response . | All responses total n = 181 n (%) . | Sustained response . | ||
|---|---|---|---|---|
| Total n = 181 n (%) . | 400-mg dose group n = 62 n (%) . | 600-mg dose group n = 119 n (%) . | ||
| Overall* | 149 (82) | 125 (69) | 40 (65) | 85 (71) |
| 95% CI | 76.0-87.6 | 61.8-75.7 | 51.3-76.3 | 62.4-79.3 |
| Complete | 96 (53) | 61 (34) | 17 (27) | 44 (37) |
| Marrow response | 19 (10) | 22 (12) | 6 (10) | 16 (13) |
| Return to chronic phase | 34 (19) | 42 (23) | 17 (27) | 25 (21) |
| No response | 25 (14) | 46 (25) | 20 (32) | 26 (22) |
| Not evaluable | 7 (4) | 10 (6) | 2 (3) | 8 (7) |
| Hematologic response . | All responses total n = 181 n (%) . | Sustained response . | ||
|---|---|---|---|---|
| Total n = 181 n (%) . | 400-mg dose group n = 62 n (%) . | 600-mg dose group n = 119 n (%) . | ||
| Overall* | 149 (82) | 125 (69) | 40 (65) | 85 (71) |
| 95% CI | 76.0-87.6 | 61.8-75.7 | 51.3-76.3 | 62.4-79.3 |
| Complete | 96 (53) | 61 (34) | 17 (27) | 44 (37) |
| Marrow response | 19 (10) | 22 (12) | 6 (10) | 16 (13) |
| Return to chronic phase | 34 (19) | 42 (23) | 17 (27) | 25 (21) |
| No response | 25 (14) | 46 (25) | 20 (32) | 26 (22) |
| Not evaluable | 7 (4) | 10 (6) | 2 (3) | 8 (7) |
Overall hematologic response is complete response, marrow response, and return to chronic phase.